FDA accepts resubmitted NDA for Ironshore's HLD200 for ADHD

The Ironshore Pharmaceuticals & Development Inc. subsidiary of Highland Therapeutics Inc. (Toronto, Ontario) said FDA accepted a resubmitted NDA for HLD200 to treat ADHD. The PDUFA date is Aug. 8...